
NeOnc Technologies FDA Meeting Rescheduled for NEO212 Development
NeOnc Technologies Holdings, Inc. announced that the FDA has rescheduled its End-of-Phase 1 Type B meeting for oral NEO212 to November 23, 2026. The meeting will focus on seeking FDA feedback for the Phase 2 development program of NEO212, including trial design, patient population, and regulatory pathways. This follows the completion of the Phase 1 dose-escalation, where 610 mg was selected as the recommended Phase 2 dose after a dose-limiting toxicity was observed at 810 mg. The company previously reported encouraging clinical activity in Phase 1, including a partial response in a glioblastoma patient and stable disease in a brain cancer patient. NeOnc plans to host an investor webinar after receiving the FDA's official meeting minutes.
Key Highlights
- FDA rescheduled End-of-Phase 1 Type B meeting for NEO212 to November 23, 2026.
- NeOnc to seek FDA feedback on Phase 2 development program for NEO212.
- Phase 1 dose escalation completed; 610 mg selected as recommended Phase 2 dose.
- Encouraging clinical activity observed in Phase 1, including partial response in GBM patient.
- FDA authorized NeOnc to proceed with Phase 2a and Phase 2b portions in September 2025.
Price Impact
More from NTHI